Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On February15, 2018, Synergy Pharmaceuticals Inc. (the “Company”) presented its corporate slide presentation to attendees at the Leerink Partners 7thAnnual Global Healthcare Conference . A copy of the presentation is attached as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.
The information in this Item 7.01 and the document attached as Exhibit99.1 are being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SYNERGY PHARMACEUTICALS, INC. ExhibitEX-99.1 2 a18-6057_2ex99d1.htm EX-99.1 Exhibit 99.1 LEERINK HEALTHCARE CONFERENCE February 15,…To view the full exhibit click here
About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.
